<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00383721</url>
  </required_header>
  <id_info>
    <org_study_id>P04230</org_study_id>
    <secondary_id>Doc ID: 3227335,</secondary_id>
    <secondary_id>Eudract No: 2006-002309-30,</secondary_id>
    <nct_id>NCT00383721</nct_id>
  </id_info>
  <brief_title>Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED)</brief_title>
  <official_title>A Randomized, 26-Week, Placebo-Controlled Efficacy and Safety Study With a 26-Week Long-Term Safety Extension, of High- and Medium-Dose Inhaled Mometasone Furoate/Formoterol Fixed-Dose Combination Formulation Compared With Formoterol and High-Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled, parallel-group, multi-site, double-blind study
      evaluating the efficacy of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler
      (MDI) 400/10 mcg twice daily (BID) and MF/F MDI 200/10 mcg BID compared with MF 400 mcg BID
      and F 10 mcg BID in adults at least 40 years of age, with moderate to severe chronic
      obstructive pulmonary disease (COPD). All placebo-treated subjects and active-treated
      subjects who will not participate in the safety extension will be discontinued and will have
      their Final Visit at Week 26. Subjects who continue into the 26-week safety extension will
      have their Final Visit at Week 52. Efficacy will be measured by the mean change from Baseline
      to Week 13 in area under the forced expiratory volume in one second concentration time curve
      from 0 to 12 hours (FEV1 AUC[0-12hr]) and change from Baseline to Week 13 in AM predose FEV1.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 13 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)</measure>
    <time_frame>Baseline to Endpoint (13 weeks)</time_frame>
    <description>FEV1 AUC was standardized to liters. Endpoint was the last post-baseline non-missing result through Week 13 carried forward.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline to Week 13 Endpoint in AM Predose FEV1</measure>
    <time_frame>Baseline to Endpoint (13 weeks)</time_frame>
    <description>Endpoint was the last post-baseline non-missing result through Week 13 carried forward.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in St George's Respiratory Questionaire (SGRQ) Total Score</measure>
    <time_frame>Baseline to Endpoint (26 weeks)</time_frame>
    <description>SGRQ consisted of 76 items aggregated into 3 component scores: symptoms
(frequency/severity), activity (cause or limited by breathlessness), impact (social functioning, psychological disturbances from airway disease), &amp; total score. Best health scores have a low numeric value. All component scores &amp; total score ranged from 0-100, with a higher score indicating greater disease burden. A 4-point increase over placebo (and Baseline) was considered the minimum clinically important difference. Endpoint was the last post-baseline non-missing result through the 26 week evaluation carried forward.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Proportion of Chronic Obstructive Pulmonary Disease (COPD) Symptom-Free Nights (AM Diary Symptoms)</measure>
    <time_frame>Baseline to Endpoint (26 weeks)</time_frame>
    <description>Prior to the use of study drug rescue medication (in the morning upon awakening) the participant evaluated the COPD symptoms of wheezing, cough, and difficulty breathing. A symptom-free night was defined as a combined score of 0 (no symptoms) across all three COPD symptoms evaluated the following morning. Proportion for Baseline included data from the last week before the first dose. Proportion for Endpoint included data across the entire 26-week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Partly Stable COPD</measure>
    <time_frame>Endpoint (26 weeks)</time_frame>
    <description>Partly stable COPD was a composite measure that included the following COPD
outcomes: (1) No oral steroid rescue medication; (2) No AM or PM COPD weekly
average symptom score greater than 2 during at least 7 of 8 weeks; (3) No moderate or severe exacerbations; (4) No unscheduled visits due to COPD worsenings; (5) No study discontinuation due to treatment failure or treatment-related adverse event as determined by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Mild, Moderate, or Severe COPD Exacerbations</measure>
    <time_frame>Endpoint (26 weeks)</time_frame>
    <description>Mild = 12 or more inhalations/day of inhaled rescue medication or 2 or more
nebulized treatments/day of inhaled rescue medication. Moderate = treatment with
antibiotics or oral steroids. Severe = emergency room treatment or hospitalizations of survival curves. If an event was composed of multiple criteria, the most severe criteria was assigned to the event.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1196</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>MF/F MDI 400/10 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MF/F MDI 200/10 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MF MDI 400 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol MDI 10 mcg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MDI BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate/formoterol (MF/F) combination</intervention_name>
    <description>MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks</description>
    <arm_group_label>MF/F MDI 400/10 mcg BID</arm_group_label>
    <other_name>SCH 418131</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate/formoterol (MF/F) combination</intervention_name>
    <description>MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks</description>
    <arm_group_label>MF/F MDI 200/10 mcg BID</arm_group_label>
    <other_name>SCH 418131</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate MDI (MF MDI)</intervention_name>
    <description>MF 400 mcg via metered dose inhaler twice daily for 52 weeks</description>
    <arm_group_label>MF MDI 400 mcg BID</arm_group_label>
    <other_name>SCH 32088</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol MDI</intervention_name>
    <description>Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks</description>
    <arm_group_label>Formoterol MDI 10 mcg BID</arm_group_label>
    <other_name>Foradil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo MDI twice a day for 26 weeks</description>
    <arm_group_label>Placebo MDI BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe COPD based on prebronchodilator FEV1/forced vital capacity (FVC)
             ratio of &lt;=70%.

          -  At Screening &amp; Baseline, postbronchodilator FEV1 must be &gt;= 60% predicted normal &amp;
             &gt;=25% predicted normal.

          -  COPD symptoms for &gt;=24 months.

          -  &gt;=2 COPD exacerbations requiring course of oral corticosteroid &amp;/or antibiotics within
             2-12 months before screening.

          -  Ex- or current smoker with smoking history &gt;=10 pack years.

          -  Only albuterol/salbutamol for relief for at least 2 weeks prior to randomization.

          -  Withdraw from parenteral &amp; oral steroids, anticholinergics, &amp; antibiotics 4 weeks
             prior to Screening.

          -  No harm in changing current COPD therapy, willing to discontinue his/her
             anticholinergics, inhaled corticosteroids (ICS) or ICS/long-acting beta agonists
             (LABA) at Screening, &amp; transferred to albuterol/salbutamol for relief for 2 weeks
             prior to Randomization.

          -  Lab tests conducted at Screening must be acceptable to investigator. Electrocardiogram
             (ECG) performed at Screening or within 30 days prior to Screening must be acceptable
             to investigator. Chest X-ray or computerized tomography (CT) scan is acceptable within
             12 months prior to Screening must be acceptable to investigator.

          -  Female of childbearing potential must use birth control. Includes: hormonal
             contraceptives, intra-uterine device (IUD), condom in combination with spermicide,
             monogamous relationship with male partner who had vasectomy. Started birth control at
             least 3 months prior to Screening (exception condom), &amp; must agree to continue. Female
             who is not currently sexually active must agree/consent to using a method should she
             become sexually active. Women who have been surgically sterilized or are at least 1
             year postmenopausal are not considered to be of childbearing potential. Female must
             have negative serum pregnancy test at Screening.

        Exclusion Criteria:

          -  Evidence (upon visual inspection) of oropharyngeal candidiasis at Baseline with or
             without treatment. If there is evidence at Screening, may be treated as appropriate &amp;
             visit can be scheduled upon resolution. If there is evidence at Baseline, may be
             treated as appropriate &amp; visit can be rescheduled upon resolution.

          -  History of renal, hepatic, cardiovascular, metabolic, neurologic, hematologic,
             ophthalmological, respiratory, gastrointestinal, cerebrovascular, or other which could
             interfere with study or require treatment which might interfere with study. Examples
             include (but are not limited to) hypertension treated with beta-blockers), active
             hepatitis, coronary artery disease, arrhythmia, significant QTc prolongation (ie QTcF
             or QTcB [Fridericia or Bazett corrections, respectively &gt;500 milliseconds (msecs)])
             stroke, severe rheumatoid arthritis, chronic open-angle glaucoma or posterior
             subcapsular cataracts, acquired immune deficiency syndrome (AIDS), or conditions that
             may interfere with respiratory function such as asthma, bronchiectasis, cystic
             fibrosis. Others which are well-controlled &amp; stable (eg hypertension not requiring
             beta-blockers) will not prohibit participation if appropriate to investigator.

          -  Allergy/sensitivity to glucocorticosteroids, beta-2 agonists, study drug/excipients.

          -  Female who is breast-feeding, pregnant, or intends to become pregnant.

          -  Illicit drug user.

          -  Human immunodeficiency virus (HIV) positive (testing not conducted).

          -  Unable to correctly use oral MDI.

          -  Taking any restricted medications prior to Screening without meeting washout.

          -  Cannot adhere to permitted concomitant &amp; prohibited medications.

          -  May not participate in this same study at another investigational site. Cannot
             participate in different investigational study at any site, during same time.

          -  Not be randomized into study more than once.

          -  No person directly associated with administration of study may participate.

          -  Previously participated in MF/F trial.

          -  Increase in absolute volume of &gt;=400 milliliters (mL) at Screening or prior to
             Baseline within 30 minutes after administration of 4 inhalations of
             albuterol/salbutamol (total dose of 360 to 400 mcg), or nebulized 2.5 mg
             albuterol/salbutamol.

          -  Asthma.

          -  Lobectomy, pneumonectomy or lung volume reduction surgery.

          -  Lung cancer.

          -  Requires long-term administration of oxygen (&gt;15 hours/day).

          -  Alpha-1-antitrypsin deficiency.

          -  A history and/or presence of intraocular pressure in either eye &gt;=22 millimeters of
             mercury (mm Hg), glaucoma, and/or posterior subcapsular cataracts. A subject who has
             undergone incisional or intraocular surgery in which the natural lens is still present
             in the eye. A subject with a history of penetrating trauma to both eyes. A subject
             with one or more of the following Lens Opacities Classification System (LOCS) III
             grades at screening:

               -  nuclear opalescence (NO): &gt;=3.0,

               -  nuclear color (NC): &gt;=3.0,

               -  cortical cataract (C): &gt;=2.0,

               -  posterior subcapsular (P): &gt;=0.5.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Colombia</country>
    <country>Costa Rica</country>
    <country>Estonia</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>Tunisia</country>
    <country>Ukraine</country>
    <country>United States</country>
    <country>Venezuela</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2006</study_first_submitted>
  <study_first_submitted_qc>September 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2006</study_first_posted>
  <results_first_submitted>July 22, 2011</results_first_submitted>
  <results_first_submitted_qc>September 16, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 26, 2011</results_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>At Week 26, all participants randomized to placebo were to be discontinued, while 75% of participants randomized to an active treatment were randomly selected to participate in the 26-week Treatment Safety Extension. Several placebo-treated participants continued in error into the Treatment Safety Extension.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MF/F MDI 400/10 mcg BID</title>
          <description>Mometasone furoate/formoterol fumarate (MF/F) 400/10 mcg via a metered dose inhaler (MDI) twice daily (BID) for 52 weeks.</description>
        </group>
        <group group_id="P2">
          <title>MF/F MDI 200/10 mcg BID</title>
          <description>MF/F 200/10 mcg via a MDI BID for 52 weeks.</description>
        </group>
        <group group_id="P3">
          <title>MF MDI 400 mcg BID</title>
          <description>Mometasone furoate (MF) 400 mcg via a MDI BID for 52 weeks.</description>
        </group>
        <group group_id="P4">
          <title>F MDI 10 mcg BID</title>
          <description>Formoterol fumarate (F) 10 mcg via a MDI BID for 52 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Placebo MDI BID for 26 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>26-Week Double-Blind Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="225"/>
                <participants group_id="P2" count="239"/>
                <participants group_id="P3" count="253"/>
                <participants group_id="P4" count="243"/>
                <participants group_id="P5" count="236"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="190">1 participant listed as “ongoing” since the participant status could not be formally confirmed.</participants>
                <participants group_id="P2" count="202"/>
                <participants group_id="P3" count="202"/>
                <participants group_id="P4" count="193"/>
                <participants group_id="P5" count="169"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="67"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant withdrawal unrelated</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant withdrawal related</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet protocol eligibility</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>26-Week Treatment Safety Extension</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="153"/>
                <participants group_id="P3" count="149"/>
                <participants group_id="P4" count="148"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="136"/>
                <participants group_id="P3" count="126"/>
                <participants group_id="P4" count="131"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant withdrawal unrelated</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant withdrawal related</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet protocol eligibility</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MF/F MDI 400/10 mcg BID</title>
          <description>Mometasone furoate/formoterol fumarate (MF/F) 400/10 mcg via a metered dose inhaler (MDI) twice daily (BID) for 52 weeks.</description>
        </group>
        <group group_id="B2">
          <title>MF/F MDI 200/10 mcg BID</title>
          <description>MF/F 200/10 mcg via a MDI BID for 52 weeks.</description>
        </group>
        <group group_id="B3">
          <title>MF MDI 400 mcg BID</title>
          <description>Mometasone furoate (MF) 400 mcg via a MDI BID for 52 weeks.</description>
        </group>
        <group group_id="B4">
          <title>F MDI 10 mcg BID</title>
          <description>Formoterol fumarate (F) 10 mcg via a MDI BID for 52 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Placebo MDI BID for 26 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="225"/>
            <count group_id="B2" value="239"/>
            <count group_id="B3" value="253"/>
            <count group_id="B4" value="243"/>
            <count group_id="B5" value="236"/>
            <count group_id="B6" value="1196"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="9.1"/>
                    <measurement group_id="B2" value="60.1" spread="9.0"/>
                    <measurement group_id="B3" value="60.5" spread="8.5"/>
                    <measurement group_id="B4" value="59.7" spread="8.7"/>
                    <measurement group_id="B5" value="58.8" spread="9.5"/>
                    <measurement group_id="B6" value="59.7" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="61"/>
                    <measurement group_id="B5" value="58"/>
                    <measurement group_id="B6" value="296"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="175"/>
                    <measurement group_id="B3" value="197"/>
                    <measurement group_id="B4" value="182"/>
                    <measurement group_id="B5" value="178"/>
                    <measurement group_id="B6" value="900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 13 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)</title>
        <description>FEV1 AUC was standardized to liters. Endpoint was the last post-baseline non-missing result through Week 13 carried forward.</description>
        <time_frame>Baseline to Endpoint (13 weeks)</time_frame>
        <population>Intent-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 400/10 mcg BID</title>
            <description>Mometasone furoate/formoterol fumarate (MF/F) 400/10 mcg via a metered dose inhaler (MDI) twice daily (BID) for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MF/F MDI 200/10 mcg BID</title>
            <description>MF/F 200/10 mcg via a MDI BID for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MF MDI 400 mcg BID</title>
            <description>Mometasone furoate (MF) 400 mcg via a MDI BID for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol fumarate (F) 10 mcg via a MDI BID for 52 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo MDI BID for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 13 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)</title>
          <description>FEV1 AUC was standardized to liters. Endpoint was the last post-baseline non-missing result through Week 13 carried forward.</description>
          <population>Intent-to-treat (ITT) population</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="246"/>
                <count group_id="O4" value="236"/>
                <count group_id="O5" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.189" spread="0.408"/>
                    <measurement group_id="O2" value="1.195" spread="0.408"/>
                    <measurement group_id="O3" value="1.260" spread="0.408"/>
                    <measurement group_id="O4" value="1.176" spread="0.408"/>
                    <measurement group_id="O5" value="1.205" spread="0.408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (Change from Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.179" spread="0.274"/>
                    <measurement group_id="O2" value="0.139" spread="0.274"/>
                    <measurement group_id="O3" value="0.053" spread="0.274"/>
                    <measurement group_id="O4" value="0.092" spread="0.274"/>
                    <measurement group_id="O5" value="0.018" spread="0.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline to Week 13 Endpoint in AM Predose FEV1</title>
        <description>Endpoint was the last post-baseline non-missing result through Week 13 carried forward.</description>
        <time_frame>Baseline to Endpoint (13 weeks)</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 400/10 mcg BID</title>
            <description>Mometasone furoate/formoterol fumarate (MF/F) 400/10 mcg via a metered dose inhaler (MDI) twice daily (BID) for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MF/F MDI 200/10 mcg BID</title>
            <description>MF/F 200/10 mcg via a MDI BID for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MF MDI 400 mcg BID</title>
            <description>Mometasone furoate (MF) 400 mcg via a MDI BID for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol fumarate (F) 10 mcg via a MDI BID for 52 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo MDI BID for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 13 Endpoint in AM Predose FEV1</title>
          <description>Endpoint was the last post-baseline non-missing result through Week 13 carried forward.</description>
          <population>ITT population</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="228"/>
                <count group_id="O3" value="245"/>
                <count group_id="O4" value="235"/>
                <count group_id="O5" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.188" spread="0.408"/>
                    <measurement group_id="O2" value="1.194" spread="0.408"/>
                    <measurement group_id="O3" value="1.255" spread="0.408"/>
                    <measurement group_id="O4" value="1.175" spread="0.408"/>
                    <measurement group_id="O5" value="1.205" spread="0.408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (Change from Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.098" spread="0.280"/>
                    <measurement group_id="O2" value="0.063" spread="0.280"/>
                    <measurement group_id="O3" value="0.028" spread="0.280"/>
                    <measurement group_id="O4" value="0.049" spread="0.280"/>
                    <measurement group_id="O5" value="-0.003" spread="0.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.062</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.583</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in St George's Respiratory Questionaire (SGRQ) Total Score</title>
        <description>SGRQ consisted of 76 items aggregated into 3 component scores: symptoms
(frequency/severity), activity (cause or limited by breathlessness), impact (social functioning, psychological disturbances from airway disease), &amp; total score. Best health scores have a low numeric value. All component scores &amp; total score ranged from 0-100, with a higher score indicating greater disease burden. A 4-point increase over placebo (and Baseline) was considered the minimum clinically important difference. Endpoint was the last post-baseline non-missing result through the 26 week evaluation carried forward.</description>
        <time_frame>Baseline to Endpoint (26 weeks)</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 400/10 mcg BID</title>
            <description>Mometasone furoate/formoterol fumarate (MF/F) 400/10 mcg via a metered dose inhaler (MDI) twice daily (BID) for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MF/F MDI 200/10 mcg BID</title>
            <description>MF/F 200/10 mcg via a MDI BID for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MF MDI 400 mcg BID</title>
            <description>Mometasone furoate (MF) 400 mcg via a MDI BID for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol fumarate (F) 10 mcg via a MDI BID for 52 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo MDI BID for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in St George's Respiratory Questionaire (SGRQ) Total Score</title>
          <description>SGRQ consisted of 76 items aggregated into 3 component scores: symptoms
(frequency/severity), activity (cause or limited by breathlessness), impact (social functioning, psychological disturbances from airway disease), &amp; total score. Best health scores have a low numeric value. All component scores &amp; total score ranged from 0-100, with a higher score indicating greater disease burden. A 4-point increase over placebo (and Baseline) was considered the minimum clinically important difference. Endpoint was the last post-baseline non-missing result through the 26 week evaluation carried forward.</description>
          <population>ITT population</population>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="227"/>
                <count group_id="O3" value="240"/>
                <count group_id="O4" value="231"/>
                <count group_id="O5" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.22" spread="17.49"/>
                    <measurement group_id="O2" value="47.29" spread="17.49"/>
                    <measurement group_id="O3" value="48.27" spread="17.49"/>
                    <measurement group_id="O4" value="46.27" spread="17.49"/>
                    <measurement group_id="O5" value="46.59" spread="17.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (Change from Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.04" spread="13.95"/>
                    <measurement group_id="O2" value="-7.99" spread="13.95"/>
                    <measurement group_id="O3" value="-5.87" spread="13.95"/>
                    <measurement group_id="O4" value="-4.93" spread="13.95"/>
                    <measurement group_id="O5" value="-2.88" spread="13.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Proportion of Chronic Obstructive Pulmonary Disease (COPD) Symptom-Free Nights (AM Diary Symptoms)</title>
        <description>Prior to the use of study drug rescue medication (in the morning upon awakening) the participant evaluated the COPD symptoms of wheezing, cough, and difficulty breathing. A symptom-free night was defined as a combined score of 0 (no symptoms) across all three COPD symptoms evaluated the following morning. Proportion for Baseline included data from the last week before the first dose. Proportion for Endpoint included data across the entire 26-week treatment period.</description>
        <time_frame>Baseline to Endpoint (26 weeks)</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 400/10 mcg BID</title>
            <description>Mometasone furoate/formoterol fumarate (MF/F) 400/10 mcg via a metered dose inhaler (MDI) twice daily (BID) for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MF/F MDI 200/10 mcg BID</title>
            <description>MF/F 200/10 mcg via a MDI BID for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MF MDI 400 mcg BID</title>
            <description>Mometasone furoate (MF) 400 mcg via a MDI BID for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol fumarate (F) 10 mcg via a MDI BID for 52 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo MDI BID for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Proportion of Chronic Obstructive Pulmonary Disease (COPD) Symptom-Free Nights (AM Diary Symptoms)</title>
          <description>Prior to the use of study drug rescue medication (in the morning upon awakening) the participant evaluated the COPD symptoms of wheezing, cough, and difficulty breathing. A symptom-free night was defined as a combined score of 0 (no symptoms) across all three COPD symptoms evaluated the following morning. Proportion for Baseline included data from the last week before the first dose. Proportion for Endpoint included data across the entire 26-week treatment period.</description>
          <population>ITT population</population>
          <units>Proportion of symptom-free nights</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="228"/>
                <count group_id="O3" value="242"/>
                <count group_id="O4" value="234"/>
                <count group_id="O5" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.334"/>
                    <measurement group_id="O2" value="0.22" spread="0.334"/>
                    <measurement group_id="O3" value="0.24" spread="0.334"/>
                    <measurement group_id="O4" value="0.25" spread="0.334"/>
                    <measurement group_id="O5" value="0.24" spread="0.334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (Change from Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.29"/>
                    <measurement group_id="O2" value="0.17" spread="0.29"/>
                    <measurement group_id="O3" value="0.16" spread="0.29"/>
                    <measurement group_id="O4" value="0.13" spread="0.29"/>
                    <measurement group_id="O5" value="0.12" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Partly Stable COPD</title>
        <description>Partly stable COPD was a composite measure that included the following COPD
outcomes: (1) No oral steroid rescue medication; (2) No AM or PM COPD weekly
average symptom score greater than 2 during at least 7 of 8 weeks; (3) No moderate or severe exacerbations; (4) No unscheduled visits due to COPD worsenings; (5) No study discontinuation due to treatment failure or treatment-related adverse event as determined by the investigator.</description>
        <time_frame>Endpoint (26 weeks)</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 400/10 mcg BID</title>
            <description>Mometasone furoate/formoterol fumarate (MF/F) 400/10 mcg via a metered dose inhaler (MDI) twice daily (BID) for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MF/F MDI 200/10 mcg BID</title>
            <description>MF/F 200/10 mcg via a MDI BID for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MF MDI 400 mcg BID</title>
            <description>Mometasone furoate (MF) 400 mcg via a MDI BID for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol fumarate (F) 10 mcg via a MDI BID for 52 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo MDI BID for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Partly Stable COPD</title>
          <description>Partly stable COPD was a composite measure that included the following COPD
outcomes: (1) No oral steroid rescue medication; (2) No AM or PM COPD weekly
average symptom score greater than 2 during at least 7 of 8 weeks; (3) No moderate or severe exacerbations; (4) No unscheduled visits due to COPD worsenings; (5) No study discontinuation due to treatment failure or treatment-related adverse event as determined by the investigator.</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="235"/>
                <count group_id="O3" value="249"/>
                <count group_id="O4" value="239"/>
                <count group_id="O5" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="98"/>
                    <measurement group_id="O5" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Mild, Moderate, or Severe COPD Exacerbations</title>
        <description>Mild = 12 or more inhalations/day of inhaled rescue medication or 2 or more
nebulized treatments/day of inhaled rescue medication. Moderate = treatment with
antibiotics or oral steroids. Severe = emergency room treatment or hospitalizations of survival curves. If an event was composed of multiple criteria, the most severe criteria was assigned to the event.</description>
        <time_frame>Endpoint (26 weeks)</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 400/10 mcg BID</title>
            <description>Mometasone furoate/formoterol fumarate (MF/F) 400/10 mcg via a metered dose inhaler (MDI) twice daily (BID) for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MF/F MDI 200/10 mcg BID</title>
            <description>MF/F 200/10 mcg via a MDI BID for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MF MDI 400 mcg BID</title>
            <description>Mometasone furoate (MF) 400 mcg via a MDI BID for 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol fumarate (F) 10 mcg via a MDI BID for 52 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo MDI BID for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Mild, Moderate, or Severe COPD Exacerbations</title>
          <description>Mild = 12 or more inhalations/day of inhaled rescue medication or 2 or more
nebulized treatments/day of inhaled rescue medication. Moderate = treatment with
antibiotics or oral steroids. Severe = emergency room treatment or hospitalizations of survival curves. If an event was composed of multiple criteria, the most severe criteria was assigned to the event.</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="235"/>
                <count group_id="O3" value="249"/>
                <count group_id="O4" value="239"/>
                <count group_id="O5" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="61"/>
                    <measurement group_id="O5" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Treatment period for adverse events was 52 weeks for MF/F MDI 400/10 mcg BID,
MF/F MDI 200/10 mcg BID, MF MDI 400 mcg BID, and F MDI 10 mcg BID and 26
weeks for placebo.</desc>
      <group_list>
        <group group_id="E1">
          <title>MF/F MDI 400/10 mcg BID</title>
          <description>Mometasone furoate/formoterol fumarate (MF/F) 400/10 mcg via a metered dose inhaler (MDI) twice daily (BID) for 52 weeks.</description>
        </group>
        <group group_id="E2">
          <title>MF/F MDI 200/10 mcg BID</title>
          <description>MF/F 200/10 mcg via a MDI BID for 52 weeks.</description>
        </group>
        <group group_id="E3">
          <title>MF MDI 400 mcg BID</title>
          <description>Mometasone furoate (MF) 400 mcg via a MDI BID for 52 weeks.</description>
        </group>
        <group group_id="E4">
          <title>F MDI 10 mcg BID</title>
          <description>Formoterol fumarate (F) 10 mcg via a MDI BID for 52 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Placebo MDI BID for 26 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="239"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="243"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cardio failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cataract nuclear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cataract subcapsular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Lenticular opacities</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Gastric atrophic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Amoebic dysentery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="253"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Pumonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Rectal abcess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Collapse of lung</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lip neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Malignant palate neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Hypoxic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="225"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="239"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="253"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="243"/>
                <counts group_id="E5" events="14" subjects_affected="13" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="239"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="243"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="225"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="239"/>
                <counts group_id="E3" events="21" subjects_affected="14" subjects_at_risk="253"/>
                <counts group_id="E4" events="13" subjects_affected="12" subjects_at_risk="243"/>
                <counts group_id="E5" events="11" subjects_affected="9" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="225"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="239"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="253"/>
                <counts group_id="E4" events="13" subjects_affected="10" subjects_at_risk="243"/>
                <counts group_id="E5" events="13" subjects_affected="11" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="225"/>
                <counts group_id="E2" events="24" subjects_affected="12" subjects_at_risk="239"/>
                <counts group_id="E3" events="21" subjects_affected="16" subjects_at_risk="253"/>
                <counts group_id="E4" events="29" subjects_affected="11" subjects_at_risk="243"/>
                <counts group_id="E5" events="20" subjects_affected="14" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator has the right to publish or publicly present results. The investigator agrees not to publish or publicly present any interim results without prior written consent of the sponsor. The investigator agrees to provide to the sponsor 45 days before submission for publication that
report results of the study. The sponsor shall have the right to review &amp; comment with respect to publications, abstracts, slides, &amp; manuscripts &amp; the right to review &amp; comment on the data &amp; presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

